February 2024

Seeking blockbuster status, UCB eyes four new indications for psoriasis med Bimzelx in 2024

Seeking blockbuster status, UCB eyes four new indications for psoriasis med Bimzelx in 2024

After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels. This year, the company is focused on growing its blockbuster hopeful Bimzelx and tacking on four extra indications for the psoriasis med, alongside other launches. After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” […]

Seeking blockbuster status, UCB eyes four new indications for psoriasis med Bimzelx in 2024 Read More »

Apellis cites current challenges with Syfovre launch but bright prospects in the long term

Apellis cites current challenges with Syfovre launch but bright prospects in the long term

The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a roller-coaster ride. And there’s still more loops to negotiate. On Tuesday, when Apellis presented its quarterly earnings, its report raised more questions about Syfovre than it answered. The Massachusetts company is not guiding to a quarterly or annual

Apellis cites current challenges with Syfovre launch but bright prospects in the long term Read More »

Rovi wins FDA nod to make Moderna’s COVID vaccine at Spanish plant

Rovi wins FDA nod to make Moderna’s COVID vaccine at Spanish plant

As part of a long-term partnership between Spain’s Laboratorios Farmacéuticos Rovi and Moderna, the former company is bringing a new plant into the mix for production of COVID-19 vaccines bound for the U.S. market. During an inspection in January, FDA staffers were satisfied with Rovi’s active substance manufacturing plant in Granada, Spain, effectively allowing Spikevax doses made

Rovi wins FDA nod to make Moderna’s COVID vaccine at Spanish plant Read More »

After Idorsia deal, Viatris’ dealmaking appetite remains strong, CEO says

After Idorsia deal, Viatris’ dealmaking appetite remains strong, CEO says

On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business development grabs—especially on the commercial side—executives said on a call with analysts Wednesday. Viatris will continue to entertain “all manner” of deals to bulk up its portfolio, CEO Scott

After Idorsia deal, Viatris’ dealmaking appetite remains strong, CEO says Read More »

Bolstering US presence, Australia’s Telix moves to acquire Texas CDMO IsoTherapeutics

Bolstering US presence, Australia’s Telix moves to acquire Texas CDMO IsoTherapeutics

Telix Pharmaceuticals moved to acquire Texas-based CDMO IsoTherapeutics in a cash and stock deal valued at $13.6 million, expanding the Australian biotech’s manufacturing footprint in the U.S. Under the terms of the deal, Telix will shell out $2 million in cash and $6 million in shares upfront with and additional $5 million in cash linked to

Bolstering US presence, Australia’s Telix moves to acquire Texas CDMO IsoTherapeutics Read More »

After steep cost cuts, Novavax’s fourth-quarter performance falls short of expectations

After steep cost cuts, Novavax’s fourth-quarter performance falls short of expectations

As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. The company’s loss per share of $1.44 exceeded analyst expectations of 45 cents per share, CNBC reports, while its fourth-quarter revenues of $291.3 million came short of the analysts’ estimate of $322 million. Novavax’s

After steep cost cuts, Novavax’s fourth-quarter performance falls short of expectations Read More »

SC to Centre: Take call on standard hospital charges or we may slap CGHS rates – ET HealthWorld

SC to Centre: Take call on standard hospital charges or we may slap CGHS rates – ET HealthWorld

New Delhi: A cataract surgery could cost up to Rs 10,000 per eye in a govt hospital and Rs 30,000-1,40,000 in a private facility. Supreme Court Tuesday took strong exception to this disparity and inability of the Centre to implement a 14-year-old law-Clinical Establishment (Central Government) Rules-mandating notification of a standard rate in consultation with

SC to Centre: Take call on standard hospital charges or we may slap CGHS rates – ET HealthWorld Read More »

Pre COVID only 20 per cent of online consults were via video, now 90 per cent: Practo   – Express Healthcare

Pre COVID only 20 per cent of online consults were via video, now 90 per cent: Practo   – Express Healthcare

Pre COVID only 20 per cent of online consults were via video, now 90 per cent: Practo   – Express Healthcare Home News Pre COVID only 20 per cent of online consults were via video, now 90 per cent: Practo   You cannot print contents of this website. Source link

Pre COVID only 20 per cent of online consults were via video, now 90 per cent: Practo   – Express Healthcare Read More »

Reusable ECGI vest successfully detects early signs of inherited hypertrophic cardiomyopathy – PharmaTimes

Reusable ECGI vest successfully detects early signs of inherited hypertrophic cardiomyopathy – PharmaTimes

The inherited fatal heart muscle condition affects one in every 500 adults in the UK Researchers from University College London (UCL) have developed a reusable electrocardiographic imaging (ECGI) vest to detect early signs and abnormalities in hypertrophic cardiomyopathy. Published in the Journal of the American College of Cardiology, the study suggests that the ECGI vest

Reusable ECGI vest successfully detects early signs of inherited hypertrophic cardiomyopathy – PharmaTimes Read More »

ICR study reveals new targeted immunotherapy to prevent spread of breast cancer – PharmaTimes

ICR study reveals new targeted immunotherapy to prevent spread of breast cancer – PharmaTimes

Breast cancer is responsible for around 47,000 new cases in England every year Researchers from the Institute of Cancer Research (ICR) have revealed a new type of targeted immunotherapy to help prevent the growth and spread of tumours in breast cancers. Published in the Journal for ImmunoTherapy of Cancer, the new research was funded by

ICR study reveals new targeted immunotherapy to prevent spread of breast cancer – PharmaTimes Read More »

Scroll to Top